{"ModuleTitle": "Company Description", "CompanyName": "Neurocrine Biosciences, Inc.", "Symbol": "NBIX", "Address": "12780 EL CAMINO REAL, SAN DIEGO, California, 92130, United States of America", "Phone": "(858) 617-7600", "Industry": "Biotechnology: Biological Products (No Diagnostic Substances)", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a commercial-stage biopharmaceutical company focused on discovering and\r\ndeveloping innovative and life-changing treatments for patients with serious,\r\nchallenging and under-addressed neurological, endocrine and psychiatric\r\ndisorders. We specialize in targeting and interrupting disease-causing\r\nmechanisms involving the interconnected pathways of the nervous and endocrine\r\nsystems. Currently, we are primarily focused on the commercialization of\r\nINGREZZA\u00ae (valbenazine) in the United States, or U.S., our first U.S. Food and\r\nDrug Administration, or FDA, approved product.\r\n\r\nIn April 2017, we received FDA approval of our first product, INGREZZA, for the\r\ntreatment of adults with tardive dyskinesia, or TD. Shortly after receiving FDA\r\napproval, we began commercializing INGREZZA in the U.S. using a specialty sales\r\nforce primarily focused on educating physicians who treat patients with TD,\r\nincluding psychiatrists and neurologists.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f07%2f0001564590-20-003773.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Bill Wilson", "title": "Vice President-Information Technology & Operations"}, {"name": "Dimitri E. Grigoriadis", "title": "Chief Research Officer"}, {"name": "Eiry W. Roberts", "title": "Chief Medical Officer"}, {"name": "Kevin Charles Gorman", "title": "Chief Executive Officer & Director"}, {"name": "Matthew C. Abernethy", "title": "Chief Financial Officer"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}